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Introduction
Ovarian cancer is an infrequent tumor 
showing early silent metastatic growth 
and high recurrence rates. The treatment 
management depends on staging; advanced 
stages in particular need to be accurately 
assessed for optimal therapeutic management 
[1]. The correct staging helps surgeons to 
achieve complete tumor resection, as the 
extent of residual disease is one of the most 
crucial prognostic factors for patients with 
ovarian cancer [2,3]. The gold standard for 
imaging in the pre-operative staging of 
ovarian cancer is still body (chest, abdomen, 
pelvis) contrast enhanced computed 
tomography (CECT). The accuracy of CECT 
is similar to that of conventional magnetic 
resonance imaging (MRI) (ranging from 
53% - 92% vs. 78% - 93%, respectively [4-
6]. The higher field strength 3T MRI may 
possess accuracy comparable to surgical 
staging of ovarian cancer, because in simple 
terms, 3T MRI has twice the strength of 1.5T 
MRI and provides more information about 
structure and function of tissues, in half 
the time of the 1.5T machines [7]. The most 
important limitations of CT in the staging 
of ovarian cancer include the challenge of 
identifying small peritoneal metastases and 
the difficulty in differentiating between 
malignant and benign ovarian masses [8]. 
CT also lacks functional information, which 
could help to define lymph nodes as metastatic 
by using criteria other than just size. 
The degree of restriction to water diffusion 
in biological tissues is inversely correlated 
to the tissue cellularity and the integrity 
of cell membranes. Such imaging can be 
performed quickly without the need for the 
administration of exogenous contrast medium 
[9]. Recent advances have enabled diffusion 
weighted imaging (DWI) to be widely used 
for tumor evaluation in the abdomen and 
pelvis and furthermore, whole-body DWI 
Abstract
Purpose: To investigate the value of 3T diffusion weighted magnetic resonance imaging (DW-MRI) 
compared to contrast enhanced computed tomography (CECT), in the preoperative staging of patients 
with suspected ovarian cancer (OC) or with suspected recurrence of ovarian cancer (ROC).
Materials and methods: Thirty-two women (mean age 65 ± 14) with suspected (n = 23) or recurrent 
(n = 9) ovarian cancer were included prospectively in a single center study. CECT and abdominal 3T 
DW-MRI were performed.  Both methods were used to independently score the presence of 1) ovarian 
tumor, 2) peritoneal or omental carcinomatosis, 3) pathological lymph nodes (LN), along with 4) liver 
parenchymal, 5) liver capsular, 6) diaphragmatic, and 7) extra-abdominal metastases.  Findings were 
scored as: 0=benign, 1=suspicious for malignancy, or 2=definitely malignant. In addition, the lowest 
ADC values were measured in existing primary tumors.  The extent of disease burden and correlation to 
histopathological findings were analyzed.
Results: The mean disease score was higher in DW-MRI than in CT (4.9 ± 2.6 vs. 3.5 ± 2.2, P < 0.001). 
Compared to CT, DW-MRI depicted more LN (P = 0.001) and diaphragmatic (P = 0.024) lesions. The 
lowest ADC values were significantly lower in malignant tumors (n = 18) than in benign tumors (n = 5) 
(0.640 x10-3mm2/s ± 159 vs. 0.992 x10-3mm2/s ± 218, P = 0.002).
Conclusion: The results of our prospective single center study show incremental value of abdominal 
3T DW-MRI in comparison with CECT, especially in detecting diaphragmatic and peritoneal ovarian 
cancer metastases, excluding lymph nodal metastases and in differentiating malignant adnexal tumors 
from benign.
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were acquired in a single breath hold that lasted 20 s (see 
Table 1 for parameter details). ADC-maps were automatically 
generated for b-values of 0 and 600. Anti-peristaltic drugs and 
rectal or vaginal gel were not used. The patients were allowed to 
have a light meal before imaging, but a number of them fasted. 
CT Imaging: CECT scans were performed with a 16- or 
64-detector row scanner (Somatom Sensation 16 or Somatom 
Definition AS64; Siemens Medical Systems, Erlangen, 
Germany) with intravenous contrast (iohexol [Omnipaque 350 
mg/ml; GE Healthcare, Oslo, Norway] or iobitridol [Xenetix 
350 mg I/ml], bolus 100 ml, flow rate 4 ml/s) in the portal 
venous phase from the thoracic apex to the symphysis pubis 
(body-CECT), or from the phrenicocardium to the symphysis 
pubis (abdominal CECT) without ingestion of oral contrast 
material. CECTs were reconstructed from coronal and 
transverse 3-5 mm thick slices.
Image Analysis and Scoring
Diffusion weighted MRIs (n = 32) were prospectively 
interpreted by Observer 1. Observer 2 retrospectively and 
independently interpreted DW-MRIs of the patients with 
existing primary tumors (n = 23). Both Observers were blinded 
to the CECT and to intra-operative and histopathological 
findings. Observer 1 is a radiology resident and specialist in 
gynecology with two years of experience in gynecological 
imaging, Observer 2 a radiologist with 10 years of experience 
is a recent development that shows substantial promise for 
tumor detection, but requires further evaluation [10]. In the 
recent published study, the whole-body DW-MRI showed 
more accuracy in the characterization of primary tumors and 
peritoneal staging in patients with suspected ovarian cancer 
(OC) compared with CT and 18F-fluorodeoxyglucose positron 
emission tomography/ computed tomography (FDG-PET/
CT) [11]. It has been proposed that DW-MRI might become 
part of the standard imaging protocol for the evaluation of 
the female pelvis [12]. Thus, the study results so far have been 
controversial with existing overlap in apparent diffusion 
coefficient (ADC) values of adnexal masses. Some studies have 
shown significant differences between the mean ADC values 
of benign and malignant ovarian masses [13,14] while other 
studies do not confirm this [15,16]. 
Accordingly, the purpose of the current study was to 
evaluate the incremental value of abdominal 3T DW-MRI 
and assessment of ADC values as compared to CECT in the 
preoperative staging of patients with suspected ovarian cancer 
or with suspected recurrence of ovarian cancer. 
Materials and methods
Study Design
Thirty-two women (mean age 65 ± 14 years) constituted 
the study population of our prospective single center study. 
The study protocol was approved by the ethical committee 
of our University Hospital and written informed consent 
was obtained from study subjects. The patients were enrolled 
consecutively between January 2012 and December 2012 
if ovarian cancer (n = 23) or a recurrence of ovarian cancer 
(ROC, n = 9) was suspected by a gynaecological oncologist. 
The diagnostic workup included gynaecological ultrasound 
and CA-125 tumor marker assessment. All patients were 
scheduled for routine body-CT (chest, abdomen and pelvis, 
n = 17) or abdominal (abdomen and pelvis, n = 15) CECT 
and 3T abdominal MRI in close proximity, optimally on the 
same day. The primary tumor size, tumoŕ s cystic character 
(cystic or not cystic) and the amount of ascites (no ascites, 
minor or major amount of ascites, estimated by readers) 
were recorded. The location and the size of metastatic lesions 
were reported. Largest diameter of primary and metastatic 
masses and shortest diameter of regional lymph nodes were 
measured. Baseline CA-125 values and the kinetics of CA-
125 changes in ROC patients at the time of the recurrence 
suspicion were registered. Patients with imaging artefacts (n 
= 2) were excluded, one due to hip prosthesis and one due 
to lack of cooperation with breathing instructions. Patients 
subsequently diagnosed with malignancies other than ovarian 
cancer (n = 3), or benign diseases (n = 5), were not excluded to 
be able to analyze differential diagnostic performance of 3T 
MRI between ovarian cancer, other malignancies and benign 
tumors, similar to the daily evaluation procedure in clinical 
practice. 
Imaging protocols
MR Imaging: MRI (3 T, Philips Achieva TX, Philips 
Medical Systems, Best, The Netherlands) protocols used a body 
coil (Sense-XL-Torso) for the lower and upper abdomen with 
imaging from the symphysis to the phrenicocardium, and 
included transaxial and sagittal T2-weighted (TR 651, TE 80), 
transaxial diffusion-weighted ((b-values 0, 300, 600 (sec/mm2)) 
and diffusion-weighted imaging with background body signal 
suppression (DWIBS, b-value 800) sequences. Sixteen sections 
T2 DWIBS DW-MRI
Plane Axial Axial Axial
Sequence ssTSE ssEPI ssEPI
TR (ms) 4000 5580 1831
TE (ms) 80 50 48
TI (ms) - 260 -
b-values - 800 0,300,600
Field of view (mm) 403/253 403/249 403/249
Slice thickness (mm) 5 5 5
Number of slices 46 55 46
NSA 1 5 4
Gap (mm) 0.5 0 0.5
Phase encoding steps 251 92 124
Frequency encoding 
steps 312 124 124
Echo train length 51 29 39
Sense factor 2 2 2
Scan duration 0:44 2:55 2:34
Breath hold - Yes Yes
Abbreviations: T2 = T2-weighted imaging, ssTSE = single shot 
(half-Fourier) turbo spin echo, DWIBS = diffusion weighted imaging 
with body background suppression, DW-MRI = diffusion weighted 
magnetic resonance imaging, ssEPI = ingle shot echo-planar imaging, 
TR = repetition time, TE = echo time, TI = time to inversion
Table 1. 3T MR imaging parameters for evaluation of patients with 
suspected and recurrent ovarian cancer
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Statistical Analysis
The paired samples T-test was used to compare the disease 
score sums between CECT and DW-MRI (results of Observer 
1). Wilcoxon signed ranks test was used to compare the disease 
scores in different tumor sites. One-way ANOVA was used to 
test the differences in ADC values in primary tumors. We 
examined the intra- and inter-rater repeatability of the ADC 
values by calculating intra-class correlation coefficients and 
the intra- and inter-rater repeatability of tumor site disease 
scores by calculating Kappa coefficients (κ). Statistical analysis 
was performed by using the SPSS 19.0 software package. A 
P-value < 0.05 was considered statistically significant.
Results 
Thirty-two females (mean age 65 years, range 26 - 87 years) 
were studied. Twenty-three patients (72%) were suspected to 
have ovarian cancer and nine patients (28%) were suspected to 
have recurrent ovarian cancer. The primary tumor size varied 
from 2 cm to 24 cm, with the tumor type being cystic in 80% of 
cases. The tumor marker CA 125 ranged from 5 to 5234 IU/L, 
(mean 614 IU/L). In patients with histopathological analysis of 
the primary tumor (n = 23), 15/23 (65%) patients had newly 
diagnosed ovarian cancer, three had other malignancies (13%) 
and five (22%) had a benign histological finding (Table 2). 
The mean interval between the CECT and DW-MRI 
examinations was 8 days and 16 patients (50%) had both 
examinations within 5 days. During MRI-examination 11 
patients (34%) had minor and 9 (28%) had severe ascites. MR-
imaging was feasible in all patients.
The overall disease extent score was higher in DW-MRI 
(4.9 ± 2.6) than in CT (3.5 ± 2.2, P < 0 .001). Of the seven 
different tumor sites DW-MRI disease scores were significantly 
higher than CT disease scores in lymph nodes (P = 0.001) and 
diaphragm (P = 0.024). Disease scores were not significantly 
different for CT and DW-MRI in the other sites with following 
results: primary tumor (P = 0.102), peritoneal / omental 
carcinomatosis (P = .083), liver parenchymal (P = 0.414), liver 
capsular (P = 0.317), and extra-abdominal (P = 0.114) locations.
When analysing benign (DS = 0) and definitely malignant 
(DS = 2) disease scores of primary tumors, the positive 
predictive value (PPV) of DW-MRI was 100% (TP = 16, FP = 
0) and the negative predictive value (NPV) was 67% (TN = 2, 
FN = 1). For CT, the PPV was 94% (TP = 17, FP = 1), while the 
NPV was not applicable. In further analysis, when suspicious 
for malignancy (DS = 1) and definitely malignant (DS = 2) 
disease scores were combined, the PPV and NPV for DW-MRI 
were 89% and 75%, respectively; while the PPV for CECT was 
78% (Table 3). The diagnostic accuracy of the disease scores in 
the other tumor sites is also shown in Table 3.
Lymph Node Metastases
Lymph nodes, located as para-aortic, para-caval, para-iliac 
and mesenteric or peri-portal, varied in size from 4 to 20 mm. 
By DW-MRI, the LNs were scored as definitely malignant in 
14 patients and as suspicious for malignancy in 8 cases. The 
LN-scores were equal by both modalities 18/32 times. Of the 
six discrepant cases (by DW-MRI definitely malignant / by CT 
benign) four patients underwent surgery, and three of them 
were proven to have lymph node metastases. One patient 
underwent interval debulking surgery after neoadjuvant 
chemotherapy, and metastases were found on the surface 
of the sigmoid colon and omentum, but not in the removed 
lymph nodes.
in gynecological imaging. Seven radiologists (with experience 
in gynecological CT ranging from 5 to 23 years) prospectively 
analyzed the CECT images according to established diagnostic 
criteria [17,18] and recorded the findings in a written clinical 
report as a part of their routine work. The thoracic findings 
on body-CTs were recorded, but the data was not used in the 
current study. The Observer 1, based on the prospective clinical 
reports, subsequently recorded the scorings of the CT images. 
Seven different tumor sites were evaluated: 1) the primary 
tumor (when present), 2) peritoneal or omental carcinomatosis, 
3) lymph nodes (LN), 4) liver parenchyma, 5) liver capsule, 
6) diaphragmatic surfaces and 7) extra-abdominal tumor 
locations. The disease extent in each tumor site was scored as: 
0 = benign, 1 = suspicious for malignancy and 2 = definitely 
malignant. The overall disease extent score (DS) was created 
by summing the scores of the individual tumor sites separately 
in CECT and DW-MRI. 
The overall score and site specific disease scores were 
compared between the modalities. When available, the 
accuracy of assessments was compared to the histopathological 
findings. During the visual assessment of DW images, the 
criterion for malignancy was increased signal intensity in 
the DWIBS sequence. Observed lymph nodes were evaluated 
regardless of size criteria. In quantitative analyses (adnexal 
primary tumors), ADC values were measured on an IDS5 
diagnostic workstation (version 10.2P4; Sectra Imtec, 
Linköping, Sweden) using magnified images on 1600×1200 
displays in the region with the lowest signal on T2 weighted 
images, which was interpreted to represent the most solid area 
of the tumor. The size of the regions of interest (ROI) varied 
and was held as large as possible avoiding cystic and necrotic 
areas. The measurements were repeated in at least three ROIs 
on the ADC maps and the lowest ADC value was used in the 
statistical analysis. 
Intra- and Inter-observer Analyses
To assess intra-observer repeatability, the ADC 
measurements of primary tumors and visual analyses of the 
disease scores were performed twice by Observer 1 (at least 6 
months between the two assessments). To assess inter-observer 
reproducibility, the analyses were independently performed by 
Observer 2.
Surgical Protocol
Newly diagnosed patients underwent a primary 
debulking procedure (n = 16) or interval debulking surgery 
after neoadjuvant chemotherapy (n = 4) with surgical 
histopathological staging (n = 20/23). One 80 year-old patient 
with advanced ovarian cancer received a primary tumor 
biopsy and was treated with chemotherapy (1/23). One patient 
underwent explorative laparoscopy confirming ovarian cancer 
with peritoneal carcinomatosis and metastatic diaphragmatic 
lesions (1/23). One patient with prominent ovaries and pleural 
fluid with benign cytology received a consensus diagnosis of 
benign disease during clinical follow-up (1/23).
Histopathological Protocol
Gynecological pathologist (experience more than 10 
years) from our institution interpreted the findings in a 
routine manner using the revised World Health Organization 
histologic classification for ovarian neoplasms [19].
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1 Mucinous ovarian cystadenocarcinoma 58 IC 2
2 Serous tubal intraepithelial carcinoma 65 IV 2
5 Peritoneal adenocarcinoma 74 IV
6 Ovarian carcinosarcoma 70 IIIC 3
10 Serous ovarian cystadenocarcinoma 86 IIIB 2
11 Suspected ovarian carcinoma 87 III
12 Serous ovarian carcinoma 73 IV 2
13 Mucinous ovarian carcinoma 48 IV 2
14 Serous ovarian cystadenocarcinoma 61 IV 3
15 Serous ovarian cystadenocarcinoma 71 IIIC 3
16 Mucinous ovarian cystadenocarcinoma 55 IIIC 2
17 Ovarian clear cell carcinoma 66 IV 3
20 Ovarian carcinosarcoma 58 IIIC 3
21 Serous ovarian cystadenocarcinoma 75 IV 2
30 Serous tubal carcinoma 80 IIIC 3
Recurrent ovarian cancer
4 Ovarian psammocarcinoma 29 IV 1
7 Tubal adenocarcinoma 69 IV 3
9 Ovarian adenocarcinoma 56 IIIC 3
23 Peritoneal carcinomatosis (PC) 71 IIIC 3
25 Ovarian cancer and PC 69 IV
27 Ovarian cancer 78 IV
28 Serous ovarian cystadenocarcinoma 68 IIIC 3
29 Ovarian cystadenocarcinoma 66 IV
31 Serous ovarian cancer 73 IIIC 3
24 B-cell lymphoma (bowel biopsy) 73
Other malignancy 32 Mucinous appendix carcinoma (pseudomyxoma) 57
18 Retroperitoneal leiomyosarcoma 50 IV 3
3 Uterine leiomyoma 26 benign
Benign disease
8 Endometriosis 47 benign
19 Pleural cells benign (Papa class 2), prominent ovaries 83 benign
22 Benign ovarian cystadenoma 72 benign
26 Benign mucinous cystadenoma 51 benign
 Table 2. Clinicopathological Features of Patients with Suspected and Recurrent Ovarian Cancer
Diaphragmatic Metastases
In four cases, the diaphragmatic metastatic lesions were 
only depicted in DW-MRI and were missed in CT (Figure 1). 
Lesion sizes varied from 1.2 to 1.7 cm. Two of the cases were 
histopathologically confirmed to be metastatic. Two patients 
with recurrent ovarian cancer did not undergo surgery.
Liver and Liver Capsular Metastases
One liver metastasis in a ROC patient was prospectively 
missed by CECT (Figure 2). Another liver metastasis in a newly 
diagnosed ovarian cancer patient was evaluated as suspicious 
in CECT, but definitely malignant in DW-MRI and was 
further confirmed by the surgical histopathological findings. 
One suspicious (DS = 1) liver capsular lesion was depicted by 
DW-MRI and was not confirmed by palpation in the following 
surgery. No suspicious liver capsular lesions were observed by 
CECT.
Extra-abdominal Metastases
By DW-MRI, definitely malignant extra-abdominal lesions 
were found in 10/32 patients (31%) and one suspicious lesion 
was depicted. Nine definitely malignant supradiaphragmatic 
lesions were detected in the cardiophrenic space with sizes 
ranging between 5 and 15 mm. One 14 mm lesion was located 
parasternal. Four of these ten (40%) lesions were not depicted 
in CECT (Figure 3), three in newly diagnosed patients and 
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Tumor site Imaging TP FP FN TN PPV NPV
Primary tumor DW-MRI 17 2 1 3 89 75
n = 23 CECT 18 5 0 0 78 -
PC DW-MRI 12 1 2 6 92 75
n = 21 CECT 11 2 3 5 86 63
Lymph nodes DW-MRI 6 7 0 8 46 100
n = 21 CECT 5 1 2 13 83 87
Diaphragmatic DW-MRI 6 0 1 14 100 93
n = 21 CECT 1 0 6 14 - 70
Liver parenchymal DW-MRI 1 0 - - - -
n = 21 CECT 1 0 0 0 - -
Liver capsular DW-MRI One observed lesion 





Suspected metastatic lesions in 8 patients
Suspected metastatic lesions in 5 patients
Note. ─ By two patients other histopathological correlations than primary tumor are missing: One 80 years old patient with advanced ovarian 
cancer underwent only primary tumor biopsy. One patient with prominent ovaries and pleural fluid with benign cytology received a consensus 
diagnosis of benign disease during clinical follow-up.
Figure 1. A 69-year-old woman with recurrent non-operable ovarian cancer (Stage IV). Progressive disease was suspected due to a rise of the 
tumor marker CA 125. Diaphragmatic metastases were depicted in DW MRI (5608/52, b = 800 sec/mm2) (a), but missed in CECT (b). 
Figure 2. A 68-year-old woman with recurrent serous ovarian cystadenocarcinoma (Stage IIIC). No liver lesions were depicted in a scheduled 
control whole-body CECT. After suspected liver metastasis was detected in transverse plane DW-MRI (5608, 52, b = 800 sec/mm2) (a) (arrow) 
the correlating flat lesion was found in the CECT retrospectively (b). Also seen on DW-MRI (a) the recurrence of the diaphragmatic metastasis 
(arrowhead). The patient underwent a liver-resection and diaphragmatic resection.
Table 3. Comparison of the accuracy of DW-MRI and CECT disease scores with histopathological correlation, according to tumor 
site in patients with newly diagnosed adnexal tumors. 
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Tumor type ADC lowest value
x 10-3 mm2/s
CA 125 IU/L
Ovarian cancer n=15 0.621 (0.398 - 0.814) 
in primary tumor
865 (11 - 5234)
Other malignancy 
n=3
0.736 (0.558 - 1.010) 
in primary tumor
61 (5 - 133)
Benign tumor n=5 0.992 (0.750 - 1.310) 
in primary tumor
196 (9 - 807)
Recurrent disease 
n=9
0.573 (0.451 - 0.787) 
in metastatic lesion
613 (32 - 3968)
Note.─ Data represent the mean (range).
Tumor site Intra-observer 
Cohen’s kappa (n 
= 23)
Inter-observer 
Cohen’s kappa (n 
= 23)




Lymph nodes  0.4 0.7
Diaphragm  0.5 0.3
Extra-abdominal  0.7 0.6
Liver parenchyma - -
Liver capsule - -
Note. ─ DS 0=benign, DS 1=suspicion of malignancy, DS 2=definite-
ly malignant. Liver parenchymal and liver capsular tumor sites were 
not evaluable because of too few observations.
Table 5. The intra- and inter-observer variability of DW-MRI disease 
scores between two observers when analyzing different tumor sites 
visually on the DWIBS sequence (b=800 mm2/sec). Table 4. The study populations’ ADC lowest values and tumor marker 
CA 125 levels according to histological tumor types. 
Figure 3. A 71 year-old woman with newly diagnosed Stage IIIC ovarian cancer with a suspected malignant cardiophrenic lymph node 
in DWIBS (a) (5608, 52, b=800 sec/mm2), without histopathological correlation. The same lymph node did not fulfill the size criteria for 
malignancy in CECT (b).
one in a patient with recurrent disease. Patients with the 
extra-abdominal lesions did not undergo surgery or biopsy 
according to current surgical guidelines; thus, there was no 
histopathological confirmation.
Peritoneal Metastases
In two cases, DW-MRI revealed small mesenteric, 
hyperintense nodules, which were interpreted as mesenteric 
carcinomatosis and confirmed in the debulking operation 
(Figure 4). CT missed these diagnoses. 
Primary Tumor
The false positive primary tumor with false positive 
peritoneal carcinomatosis diagnosed on CT was correctly 
excluded by high ADC value (1.310 x 10-3 mm2/s) and low SI on 
DWI and was further confirmed as advanced endometriosis. 
DW-MRI missed one primary tumor (Figure 5). The baseline 
tumour marker CA 125 (IU/L) values did not differ significantly 
between malignant and benign tumors (P = 0.654) (Table 4).
Recurrent Ovarian Cancer 
Seven of nine patients (78%) with recurrent ovarian cancer 
had an elevated tumor marker as the indication for imaging. 
The mean rise in tumor marker was 62.5% (range from 23% 
to 170%). Two patients were suspected to have recurrence by 
routine CECT. Four patients (44%) showed no or uncertain 
disease progression by CECT imaging; whereas DW-MRI 
showed a clear progression. In two cases, also recurrent 
by CT, DW-MRI depicted additional metastatic lesions in 
diaphragmatic, liver parenchymal, or parasternal locations. In 
three patients, the CECT and DW-MRI findings were identical. 
ADC Values
The lowest ADC values measured in the primary tumors 
of patients with existing histopathology (n = 23) were 
significantly lower in the malignant tumors (n = 18) compared 
with the benign tumors (n = 5) (0.640 ± 159 vs. 0.992 ± 218, P 
= 0.001). There was no significant difference of the ADC values 
between ovarian cancer and the other malignancies detected 
(P = 0.765). 
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Figure 4. Mesenterial metastases of an 80 year-old patient with a newly diagnosed serous tubal carcinoma (Stage IIIC) as shown by DWIBS 
(5608, 52, b=800 sec/mm2) (a), CECT (b) and intraoperatively (c).
Figure 5. DW-MRI missed one primary tumor in a 71 year-old 
woman with newly diagnosed serous ovarian cystadenocarcinoma 
(Stage IIIC). Intraoperatively the normal appearing ovary was buried 
in adhesive sigmoid colon (arrow) and a microscopic carcinoma was 
found on the surface of it by histopathology.
Figure 6. ADC values of malignant primary tumors were significantly 
lower than those of  benign tumors in the current study population (P 
= 0.001).
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Intra- and inter-observer intra-class correlation coefficients 
in primary tumor ADC values were 0.82 and 0.94, respectively. 
The per tumor site intra- and inter-observer agreements by 
visual analyses are shown in Table 5.
Discussion
In the current prospective single center study, we showed 
abdominal 3T DW-MRI to provide incremental diagnostic 
value in the staging of ovarian cancer and detecting 
recurrence as an adjunct to CECT. Clear difference was 
observed especially in detecting diaphragmatic and peritoneal 
metastases, excluding LN metastases and in differentiating 
malignant adnexal tumors from benign tumors.
The advantages of the non-contrast DW-MRI are that it 
is feasible in patients in whom contrast agent administration 
should be avoided and it can easily be added to any routine MR 
protocol. Using overlap techniques, we did not have difficulty 
covering the entire abdomen, which has previously been 
considered a problem [20]. Further, we consider the advantages 
of MRI such as superior soft tissue contrast to overweight 
disadvantages as longer examination time compared to 
CECT. Including MRI protocols only necessary sequences can 
shorten the acquisition time not to mention MRI technical 
developments of the last years. 
Diagnostic performance of DW-MRI and CECT in primary 
tumors and metastatic sites:
The diagnostic performance between DW-MRI and CECT 
was investigated by comparing the radiological site-specific 
disease scores with intra-operative and histopathological 
findings. Both scores, “definitely malignant” and “suspicious 
for malignancy”, counted as malignant, as counterpart to 
findings scored as clearly “benign”. In line with the results of 
the study group Michielsen et al. [21] we observed better PPVs 
of DW-MRI than CECT in the primary tumor and metastatic 
sites. In our study, the PPV of DW-MRI for primary tumor was 
89% versus 78% for CECT and respectively 92% versus 86% for 
the peritoneal carcinomatosis site. The PPV of DW-MRI for 
diaphragmatic metastatic site was 100% with six true positive 
findings as CECT missed the diaphragmatic metastatic lesions 
in six patients being false negative. On lymph nodal metastatic 
site the PPV of DW-MRI remained low (46%) reflecting 
the non-specificity of visual LN diagnostics depending on 
increased signal intensity on DW sequences leading obviously 
to overestimation. On the other hand, in LNs the NPV of 
DW-MRI was 100 % indicating that DW-MRI can reliably 
exclude LN disease extent. Altogether, we observed slightly 
better negative predictive values in all metastatic tumor sites. 
The highest NPV was found on the lymph nodal site, 100% as 
mentioned above, and the lowest on peritoneal carcinomatosis 
site 75%. Albeit, only one liver capsule metastasis occurred 
in the study population, it showed that multiple small liver 
capsule metastases were not visible in the same patient on the 
CECT scanned on the same day. 
Correct staging of ovarian cancer is crucial as it guides 
the patient management and treatment. Incremental findings 
observed by DW-MRI may play an important role in correct 
classification of patients between stages IIIC or IV and in the 
treatment decision between primary debulking surgery (PDS) 
or neoadjuvant chemotherapy (NACT) followed by interval 
debulking surgery [22]. Gynaecologist colleagues usually 
consider periportal, hepatic, mesenteric root or multiple bowel 
serosal metastasis indicating a low success rate for R0 resection 
in PDS in ovarian cancer patients. If diffusion weighted 
MRI can reliably detect these decisive lesions a diagnostic 
laparoscopy would be redundant for ovarian cancer patients 
avoiding also scarred adhesions in the following interval 
debulking operation. Further studies will show, if there will 
be a benefit for ovarian cancer patients in overall survival (OS) 
or in the recurrence rate if the therapy choice would depend 
on more sensitive DW-MRI in the future. Interestingly, 
perioperative moderate or severe morbidity as well as quality 
of life (QoL) scores were initially stated to be more favourable 
in NACT/ interval debulking surgery arm than PDS in 
advanced epithelial ovarian cancer (AEOC) patients with very 
high tumor load [23]. After completion of patient enrolment 
in this ”Scorpion” study neoadjuvant chemotherapy and 
primary debulking surgery have the same efficacy when 
used at their maximal possibilities, but the toxicity profile is 
different. Further, the Rates of complete resection (R0) were 
superior in the arm B (= neoadjuvant chemotherapy followed 
by interval debulking surgery and adjuvant chemotherapy) 
as major postoperative complications were registered, mainly 
distributed in arm A (primary debulking surgery followed 
by adjuvant chemotherapy). The differences were statistically 
significant [24].
Michielsen et al. [11] reported that confirmed peritoneal 
carcinomatosis (208 regions in 32 patients) was smaller than 
one centimetre in 36% of all peritoneal regions. The results 
of our study parallel their findings. In the current study DW-
MRI depicted hyperintense metastatic proven mesenteric 
lymph nodes with shortest diameter of six millimetres, not 
diagnosed on CT (Figre 4a). These LNs were intra-operatively 
and histopathological verified to be malignant. A pre-operative 
diagnosis of pathologic mesenteric lymph nodal site in ovarian 
cancer is relevant, because it can predict a mesenteric root 
bulky disease, which counts to one of the important advocate 
to choose NACT instead of primary debulking surgery. The 
detection of malignancy in normal size lymph nodes is known 
to be challenging and inaccurate [5,25]. Both metastatic and 
non-metastatic LNs can present with high signal intensity 
in DW-MRI; however, the mean and minimum ADC region 
values reported for metastatic nodal sites are significantly lower 
than those found at normal sites [26]. Developing quantitative 
evaluation by measuring ADC values may increase specificity 
of the LN diagnostics in the future.
The inter-observer agreement of the disease scores by visual 
analysis on DWI was perfect for peritoneal carcinomatosis 
tumor site and substantial for primary tumor and lymph nodal 
tumor site. Only fair intra-observer agreement for the lymph 
nodal site probably reflects the learning curve of the Observer 
1 and the general awareness of the tendency of DWI to rather 
poor sensitivity in LN diagnostics. The interval between the 
ratings were proceeded after at least six months. 
ADC Assessment in differentiation between benign and 
malignant adnexal lesions:
Studies about the utility of quantitative ADC values in 
ovarian cancer diagnostics exist, considered feasible and 
so being in line with the current study. In 2018, Pi et al. [27] 
estimated in their meta-analysis the diagnostic performance 
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of quantitative ADC values for predicting malignancy of 
ovarian lesions, with pooled sensitivity and specificity values 
of 0.91 and 0.91, respectively, and an AUC of 0.96. These 
findings demonstrated that quantitative ADC values are useful 
diagnostic markers for distinguishing between malignant and 
benign ovarian lesions. However, the cut-off ADC values for 
malignancy reported in their study (1.15 – 1.36 x10-3 mm2/s) 
were clearly higher than in our study where the lowest ADC 
values were significantly lower in malignant tumors than in 
benign tumors (0.640 x10-3mm2/s ± 159 vs. 0.992 x 10-3mm2/s ± 
218, P = 0.002). To notice, even despite of the same procedure, 
assessing the solid components as region of interest in 
measuring the ADC. Standardized measurement protocols 
or cut-off values are not available for ADC measurements in 
OC. The scanner type and size and positioning of regions of 
interest, and b-values vary in published studies, leading to 
differences in reported ADC values. 
Different maximal b values have been reported to calculate 
the apparent diffusion coefficient, mostly around 500 - 1000 sec/
mm2 [28]. For calculation of ADC values a monoexponential 
fit has been recommended with one b value greater than 100 
sec/mm2 and another b value greater than 500 sec/mm2 (most 
often b = 1000 sec/mm2) [29]. However, most examinations 
also include a b value of 0 sec/mm2 for easy detection of blood 
vessel anomalies. We selected b values from zero and 600 sec/
mm2 and 800 sec/mm2 for the DWIBS sequence and did not 
have problems with reduced signal to noise ratios for primary 
tumor lesion diagnoses or with the capability to differentiate 
benign from malignant lesions.
Deeper going studies on ADCs show a negative correlation 
between the mean ADC values and histologic grade and 
surgical stage [30]. Further, reduced ADCs, measured in 
whole lesion single plane-ROI, are associated with histological 
severity and worse outcome in ovarian cancer patients [31]. 
The known biological tumor heterogeneity of adnexal lesions 
creates a challenge in standardizing the ADC asssesment. In a 
previous study, a significant inverse correlation between ADC 
values and tumor cellularity in epithelial ovarian cancer was 
observed. The mean ADC value of clear cell carcinoma (CCC) 
was higher than those of HGSC and EC, seemingly due to the 
low cellularity of CCC [32].
Diagnostic performance of DW-MRI and CECT in patients 
with recurrence suspicion: 
In the current study, CECT and DW-MRI agreed in the 
findings only in three patients with the recurrent disease. 
44% of the patients with histopathological proven recurrent 
disease showed none or uncertain disease progression by 
CECT imaging whereas DW-MRI showed a clear progression. 
An uncertainty in the diagnosis of recurrent ovarian cancer 
can delate the treatment decision, which could be crucial for 
patients as in ovarian cancer the tumor marker dynamic is 
often not usable and warning clinical symptoms can be very 
unspecific. Another study showed also a better detection of 
ovarian cancer recurrence on DWI/MRI than on CT, as well 
a better prediction of complete resection of recurrent lesions 
[33].
The strength of our study is its prospective nature and its use 
in daily clinical routine in pre-operative setting and in ovarian 
cancer recurrence suspicion. Further, we strongly tested the 
power of diffusion weighted imaging technique, as our protocol 
included solely non-contrast sequences. Still, our study has 
several limitations. The number of patients is small and not 
quite all underwent surgical resection and histopathological 
confirmation. In particular, extra-abdominal and supra-
diaphragmatic lesions were not biopsied according to current 
clinical and surgical guidelines. In the future, histopathological 
confirmation of suspected cardiophrenic metastatic lesions 
should be obtained. If the DW-hyperintense cardiophrenic 
LNs can be authenticated to be metastatic, it would lead to 
upstaging of ovarian cancer. The time interval between CT 
and MRI in the current study was relatively long especially in 
a few patients with recurrent disease. Although, this counts 
to the normal management in recurrence suspicions, where 
the incremental imaging diagnostics often follow only after a 
certain clinical observation time. 
Our study protocol combined both CECT and DW-MRI 
prospectively and pre-operative. This study, as well the referred 
studies published by now, speak for supporting the DW-MRI 
to become the first-line radiological imaging modality, in both, 
the preoperative staging of ovarian cancer and in detection of 
ovarian cancer recurrence. The role of radiologist is important 
to drive this change. DWI and assessment of ADC values may 
increase radiologists’ confidence in the staging of ovarian 
cancer and differentiating malignant tumors from benign, 
supporting the patient management by gynecologists. Not to 
forget, transvaginal and Doppler ultrasound performed by 
gynecological oncologist colleagues is not likely to be omitted.
In conclusion, the results of our prospective single center 
study show incremental value of abdominal 3T DW-MRI in 
comparison with CECT, especially in detecting diaphragmatic 
and peritoneal ovarian cancer metastases, excluding lymph 
nodal metastases and in differentiating malignant adnexal 
tumors from benign. Larger-scale studies including different 
types of adnexal tumors and standardization of DW-MRI 
techniques are needed.
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